^
    Back
    Association details:
    Biomarker:RANBP2-ALK rearrangement + TNFRSF8 expression
    Cancer:Fibrosarcoma
    Drug:Zykadia (ceritinib) (ALK inhibitor) +
    Adcetris (brentuximab vedotin) (Microtubule inhibitor, CD30-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Nature
    Title:

    CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma

    Published date:
    07/20/2020
    Excerpt:
    Epithelioid inflammatory myofibroblastic sarcoma (eIMS)...Xenografts were validated by confirmation of RANBP2-ALK rearrangement, perinuclear ALK localisation and CD30 expression. Combining BV with either crizotinib or ceritinib resulted in marked tumour shrinkage in both xenograft models, and resulted in prolonged tumour-free survival...
    DOI:
    10.1038/s41416-020-0996-2